Compare · DXCM vs GMVD
DXCM vs GMVD
Side-by-side comparison of DexCom Inc. (DXCM) and G Medical Innovations Holdings Ltd. (GMVD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and GMVD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $30.78B.
- DXCM has hit the wire 15 times in the past 4 weeks while GMVD has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 1 for GMVD).
- Company
- DexCom Inc.
- G Medical Innovations Holdings Ltd.
- Price
- -
- -
- Market cap
- $30.78B
- -
- 1M return
- -3.77%
- -
- 1Y return
- +38.15%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone
- EVP Chief Legal Compliance Off Michael Jon Brown sold $141,882 worth of shares (1,700 units at $83.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 95,034 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
Latest GMVD
- SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form D filed by G Medical Innovations Holdings Ltd.
- SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)
- SEC Form 25-NSE filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.